文献速递心律失常瓣膜病与结构性心脏病

乳腺肿瘤分泌ADAM10介导心房纤维化与心房颤动

Breast tumour-secreted ADAM10 mediates atrial fibrogenesis and fibrillation.
PubMed 文献 · Eur Heart J · 2026-01-01

机制上,肿瘤分泌的可溶性ADAM10通过促进心房成纤维细胞分泌sEphrin B2并激活EphB3/EphB4受体,诱导心房纤维化,增加心房颤动易感性。

要点

  • 乳腺癌患者治疗前心房颤动患病率及心房重构指标已显著升高。
  • 肿瘤分泌的sADAM10通过sEphrin B2/EphB3/EphB4通路促进心房纤维化。
  • 抑制sADAM10可减轻乳腺癌小鼠的心房纤维化和心房颤动易感性。

核心结论

  • 乳腺癌本身即可直接诱导心房颤动,其机制涉及肿瘤分泌的sADAM10促进心房纤维化,独立于癌症治疗。

研究设计与样本

  • 建立原位乳腺癌小鼠模型(E0771细胞植入乳腺脂肪垫),并采用电生理检查、Masson染色、共培养及分子生物学技术探究机制。

主要发现

  • 匹配后乳腺癌患者(n=1217)心房颤动患病率为6.41%,显著高于对照组的0.90%。
  • 乳腺癌患者心电图V1导联P波终末力异常比例为7.37%,高于对照组的3.90%(P < .001)。
  • 乳腺癌小鼠及接受肿瘤条件培养基或乳腺癌小鼠血浆的小鼠均出现心房纤维化和心房颤动易感性增加。
  • 乳腺癌合并心房颤动患者和小鼠的肿瘤组织及血浆中sADAM10水平升高。
  • sADAM10促进心房成纤维细胞中Ephrin B2裂解为sEphrin B2,后者结合EphB3和EphB4受体激活心房纤维化通路。

临床怎么用

  • 对于乳腺癌患者,即使尚未开始抗癌治疗,也应关注心房颤动风险及心房重构迹象。
  • sADAM10及其下游sEphrin B2可能作为乳腺癌相关心房颤动的潜在治疗靶点。

局限性

  • 原文未明确报告研究的局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Breast cancer (BC)-related atrial fibrillation (AF) contributes to an overall poor prognosis and raises great concerns. However, beyond cancer treatment-related AF, it is unknown whether BC itself is sufficient to directly induce AF. This study aimed to explore the role of BC in the development of AF, focusing on the tumour itself rather than therapy-related cardiotoxicity. METHODS: A retrospective analysis was conducted on 1224 female BC patients before therapy and 18 159 healthy female participants. The prevalence of AF was assessed, and markers of atrial remodelling, including P-wave indices on electrocardiogram (ECG), were measured. An orthotopic BC model was established by implanting E0771 cells to mammary fat pads of female C57BL/6 mice. An electrophysiological study was employed to assess atrial arrhythmia vulnerability. Masson's trichrome staining, coculture assays and molecular biological techniques were used to determine the mechanisms of BC-induced AF. RESULTS: BC patients (n = 1217) were individually matched 1:1 to non-cancer female controls (n = 1217) by propensity score matching. Even before treatment, BC patients had a significantly higher prevalence of AF (6.41%) than controls (0.90%). BC patients exhibited more marked atrial remodelling evaluated by abnormal P-wave terminal force in ECG lead V1 (7.37% vs 3.90%, P < .001), compared to non-cancer female controls. Similarly, BC mice, as well as mice administered with tumour-conditioned media or plasma from BC mice, developed atrial fibrosis and had increased AF susceptibility. After screening tumour-secreted factors, both BC patients with AF and BC mice displayed elevated levels of soluble ADAM10 (sADAM10) in tumour tissue and plasma. Moreover, sADAM10 promoted the cleavage of Ephrin B2 into soluble Ephrin B2 (sEphrin B2) in atrial cardiofibroblasts (ACFs), which then bound with EphB3 and EphB4 receptors and activated the atrial fibrosis pathway. Cardiac fibroblast-specific knockdown of Ephrin B2 suppressed AF development in BC mice. The plasma levels of sEphrin B2 were especially higher in pre-treatment breast cancer patients with AF compared to controls, in parallel with increasing sADAM10 levels (R2 = 0.67, P < .0001). The inhibition of tumour-originated sADAM10 with its specific inhibitor (GI254023X) or its shRNA attenuated atrial fibrosis and AF susceptibility in BC mice. CONCLUSIONS: BC patients before treatment present a significantly higher prevalence of AF and atrial remodelling, which correlate with elevated levels of tumour-originated sADAM10 and ACF-secreted sEphrin B2. Tumour-originated sADAM10 directly promotes AF pathogenesis by inducing atrial fibrosis, independent of cancer treatment. These findings imply that the inhibition of sADAM10 represents a potentially new therapeutic option for BC-associated AF.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Xue G, Zhang P, Zhan G, et al. Breast tumour-secreted ADAM10 mediates atrial fibrogenesis and fibrillation. Eur Heart J. 2026. PMID: 41780910. doi:10.1093/eurheartj/ehag147

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。